Down 99%, biotech firm 180 Life Sciences pivots to crypto with ETH bet
The Nasdaq-listed biotechnology firm is raising $425 million for its ETH strategy, joining a parade of penny stocks investing in cryptocurrencies as their business flounders.
Archive context
Older archive item. Useful for background and entity history, but not a fresh market-moving signal.
The Nasdaq-listed biotechnology firm is raising $425 million for its ETH strategy, joining a parade of penny stocks investing in cryptocurrencies as their business flounders.
Why this matters
This ethereum story adds another data point to the current market tape and is useful when read alongside nearby source coverage.
Original source
Read on CointelegraphRelated market context
Strategy Raises $334 Million and Buys No Bitcoin With It for an Eighth Straight Week
“No bitcoin purchases or sales were made this week,” Strategy said in a Form 8-K filed Monday. The company neither bought nor sold...
Strategy sells $334 million in MSTR shares, makes no bitcoin purchases or sales as USD reserve hits $4.8 billion
Strategy's total holdings account for around 4% of the 21 million bitcoin supply cap — worth roughly $53.4 billion.
Michael Saylor’s Strategy sold $337 million worth of $MSTR stock
Saylor's capital reallocation may boost STRC confidence, potentially affecting its market value and signaling strategic shifts in...
Ripple Lands 3rd Korea Deal, Jeonbuk Bank Brings 24/7 Crypto Payments to Firms
Key Takeaways: Jeonbuk Bank is the first regional bank in Korea to use Ripple Payments. The service allows cross-border settlement...
This public company quit solar for a $5 million Bitcoin bet, now it has just $166,000 in cash
Sono Group’s transition to a Bitcoin-heavy treasury is laying bare the severe financial strain at the core of the restructured com...
Strategy CEO Sees 7 Fall Catalysts Bringing Bitcoin More Life
Strategy CEO Phong Le expects regulatory action, expanding bank participation, and digital financial products to bring more activi...